iC³: Innovation = Capital x Collaboration x Commercialization

Artificial Intelligence (AI) is driving the next wave of innovation in biotech, unlocking new possibilities in drug discovery, diagnostics, and personalized medicine. This session will explore how AI is accelerating research, improving outcomes, and reshaping the biotech landscape.

Discover the transformative impact of AI technologies and how they are paving the way for a new era in biotechnology.

As global health concerns evolve—from aging and health span to public health emergencies to biomanufacturing vulnerabilities—America’s ability to respond with speed and precision depends on strong, agile innovation ecosystems. This panel features leaders from Advanced Technology International (ATI)’s diverse portfolio of medical and health focused consortia, which represents a cross-sector engine for innovation—accelerating the development and delivery of medical advancements, diagnostics, secure supply chains, and scalable biomanufacturing.

Panelists will share how these novel public-private partnership models are transforming the government’s ability to identify needs, engage nontraditional performers, and deploy real-world solutions to meet national health priorities.

The 35th edition of the EY Biotech Beyond Borders Report finds that biopharma companies continue to face not only a challenging financing environment but also a rapidly changing political landscape. To succeed, decision-makers need to adapt their business models and operational strategies to fit today’s new norm. The Texas Edition of EY’s Biotech Beyond Borders Report offers an in-depth look at our exciting public market biotech landscape.

North Texas is establishing itself as a leader in innovative, resilient supply chain strategies that serve the broader life sciences, healthcare, and technology sectors. In a time when global logistics are increasingly tied to innovation outcomes, our region offers a unique convergence of infrastructure, industry partnerships, and entrepreneurial leadership shaping the future of supply systems.

Whether it is through the work of established hubs like DFW Airport, collaborations with global platforms like Pharma.Aero, or visionary entrepreneurs like Sharina Perry of Utopia, North Texas is charting new pathways in supply chain design, security, and sustainability. From precision logistics to novel distribution models, the region is redefining what it means to move critical products, knowledge, and technologies across the world.

A vibrant life sciences community depends on the power of the place. Regional leaders have recognized the benefit of bringing together resources, including research institutions, entrepreneurs, corporate partners, investors and nonprofits, to promote interactions -- some unexpected -- and spur growth.

North Texas has seen a wave of place-based innovation in life sciences. Recent successes include Pegasus Park in Dallas, which connects academic researchers, startups, investors and ecosystem partners; and Texas A&M's new campus in Fort Worth, which will bring industry together with multiple universities, departments and state agencies in an innovation district to transform the city's downtown.

As federal priorities shift, access to non-dilutive funding and preclinical support is more critical—and complex—than ever. This session brings together experts from D.C., academia, and state agencies to demystify the evolving landscape.

Learn how to navigate federal grants, tap into emerging resources, and align your work for long-term, mission-driven growth.

Patient advocacy ensures individuals receive the care and support they need, but true impact happens when businesses integrate patient needs into their strategies.

This session will explore how advocacy and patient-centered business models drive better healthcare outcomes.

As biotech and life sciences accelerate driven by AI, personalized medicine, and advanced therapeutics—the demand for skilled, future-ready talent is surging.

This session explores how North Texas is connecting education with opportunity to build a strong regional talent pipeline and position itself as a full-spectrum innovation hub.

Cell and gene therapies are unlocking new frontiers in medicine, offering hope for conditions once considered untreatable.

This session will dive into the transformative potential of these therapies, exploring breakthroughs in genetic medicine, the challenges of scaling and regulation, and the future impact on patient care.

As North Texas emerges as a strategic hub for cell and gene therapy manufacturing, the question is no longer “what is possible”—but “how do we scale and sustain it?”

This session brings together national and regional leaders to explore the future of biomanufacturing across cost, capacity, talent, and technology. From modular facilities to AI-integrated production lines, from public-private partnerships to accelerated timelines for rare disease therapies, we’ll examine the strategies required to move from innovation to impact at scale.With a focus on building resilient, future-ready infrastructure, this conversation will also consider what’s needed regionally to secure a lasting competitive advantage in a global biomanufacturing economy.